Andrea Riccardo Filippi1, Paolo Fava2, Serena Badellino3, Chiara Astrua2, Umberto Ricardi3, Pietro Quaglino2. 1. Department of Oncology, Radiation Oncology, University of Torino, Italy. Electronic address: andreariccardo.filippi@unito.it. 2. Department of Medical Sciences, Dermatology/Oncology, University of Torino, Italy. 3. Department of Oncology, Radiation Oncology, University of Torino, Italy.
Abstract
INTRODUCTION: The therapeutic landscape of metastatic melanoma drastically changed after the introduction of targeted therapies and immunotherapy, in particular immune checkpoints inhibitors (ICI). In recent years, positive effects on the immune system associated to radiotherapy (RT) were discovered, and radiation has been tested in combination with ICI in both pre-clinical and clinical studies (many of them still ongoing). We here summarize the rationale and the preliminary clinical results of this approach. MATERIALS AND METHODS: In the first part of this review article, redacted with narrative non-systematic methodology, we describe the clinical results of immune checkpoints blockade in melanoma as well as the biological basis for the combination of ICI with RT; in the second part, we systematically review scientific publications reporting on the clinical results of the combination of ICI and RT for advanced melanoma. RESULTS: The biological and mechanistic rationale behind the combination of ICI and radiation is well supported by several preclinical findings. Retrospective observational series and few prospective trials support the potential synergistic effect between radiation and ICI for metastatic melanoma. CONCLUSION: RT may potentiate anti-melanoma activity of ICI by enhancing response on both target and non-target lesions. Several prospective trials are ongoing with the aim of further exploring this combination in the clinical setting, hopefully confirming initial observations and opening a new therapeutic window for advanced melanoma patients.
INTRODUCTION: The therapeutic landscape of metastatic melanoma drastically changed after the introduction of targeted therapies and immunotherapy, in particular immune checkpoints inhibitors (ICI). In recent years, positive effects on the immune system associated to radiotherapy (RT) were discovered, and radiation has been tested in combination with ICI in both pre-clinical and clinical studies (many of them still ongoing). We here summarize the rationale and the preliminary clinical results of this approach. MATERIALS AND METHODS: In the first part of this review article, redacted with narrative non-systematic methodology, we describe the clinical results of immune checkpoints blockade in melanoma as well as the biological basis for the combination of ICI with RT; in the second part, we systematically review scientific publications reporting on the clinical results of the combination of ICI and RT for advanced melanoma. RESULTS: The biological and mechanistic rationale behind the combination of ICI and radiation is well supported by several preclinical findings. Retrospective observational series and few prospective trials support the potential synergistic effect between radiation and ICI for metastatic melanoma. CONCLUSION: RT may potentiate anti-melanoma activity of ICI by enhancing response on both target and non-target lesions. Several prospective trials are ongoing with the aim of further exploring this combination in the clinical setting, hopefully confirming initial observations and opening a new therapeutic window for advanced melanomapatients.
Authors: Kamran A Ahmed; Sungjune Kim; John Arrington; Arash O Naghavi; Thomas J Dilling; Ben C Creelan; Scott J Antonia; Jimmy J Caudell; Louis B Harrison; Solmaz Sahebjam; Jhanelle E Gray; Arnold B Etame; Peter A Johnstone; Michael Yu; Bradford A Perez Journal: J Neurooncol Date: 2017-05-02 Impact factor: 4.130
Authors: Lauryn R Werner; Jasdeep S Kler; Monica M Gressett; Maureen Riegert; Lindsey K Werner; Clinton M Heinze; Joseph G Kern; Mahyar Abbariki; Amy K Erbe; Ravi B Patel; Raghava N Sriramaneni; Paul M Harari; Zachary S Morris Journal: Radiother Oncol Date: 2017-09-08 Impact factor: 6.280
Authors: Muhammad Khan; Jie Lin; Guixiang Liao; Yunhong Tian; Yingying Liang; Rong Li; Mengzhong Liu; Yawei Yuan Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Aleksandra M Urbanska; Raya Khanin; Simone Alidori; Sam Wong; Barbara P Mello; Bryan Aristega Almeida; Feng Chen; Kai Ma; Melik Z Turker; Tatyana Korontsvit; David A Scheinberg; Pat B Zanzonico; Ulrich Wiesner; Michelle S Bradbury; Thomas P Quinn; Michael R McDevitt Journal: Cancer Biother Radiopharm Date: 2020-02-03 Impact factor: 3.099